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PubMed, Scopus, and Web of Science Core Collection databases were systematically 
searched for studies reporting synchronous double or multiple pituitary adenomas (MPA), 
a rare clinical condition, with a vague pathogenesis. Multiple adenomas of the pituitary 
gland are referred to as morphologically and/or immunocytochemically distinct tumors 
that are frequently small-sized and hormonally non-functional, to account for the low 
detection rate. There is no general agreement on how to classify MPA, various criteria, 
such as tumor contiguity, immunoreactivity, and clonality analysis are being used. Among 
the component tumors, prolactin (PRL)-immunopositive adenomas are highly prevalent, 
albeit mute in the majority of cases. The most frequent clinical presentation of MPA is 
Cushing’s syndrome, given the fact that in more than 50% of reported cases at least 
one lesion stains for adrenocorticotrophic hormone (ACTH). Plurihormonal hyperactivity 
may be diagnosed in a patient with MPA when more than one tumor is clinically active 
(e.g., ACTH and PRL) or in cases with at least one composite tumor (e.g., GH and PRL), 
to complicate the clinical scenario. Specific challenges associated with MPA include 
high surgical failure rates, enforcing second-look surgery in certain cases, and difficult 
preoperative neuroradiological imaging evaluation, with an overall sensitivity of only 
25% for magnetic resonance imaging to detect distinct multiple tumors. Alternatively, 
minor pituitary imaging abnormalities may raise suspicion, as these are not uncommon. 
Postoperative immunohistochemistry is mandatory and in conjunction to electron 
microscopy scanning and testing for transcription factors (i.e., Pit-1, T-pit, and SF-1) 
accurately define and classify the distinct cytodifferentiation of MPA.
Keywords: double pituitary adenomas, multiple pituitary adenomas, Cushing’s disease, acromegaly, 
immunohistochemistry, magnetic resonance imaging, pituitary transcription factor
iNTRODUCTiON
Up to 10–20% of people harbor a pituitary tumor, mostly in the form of a benign, sporadic, or familial 
(1), monoclonal, and slow-growing micro- or macroadenoma while aggressive or true malignant 
tumors constitute a rare finding (2). Pituitary adenomas provide up to 90% of the sellar and parasellar 
region masses (3), generally featuring a solitary tumor associating clinical traits attributed to pitui-
tary hormones dysfunction and/or local mass effects. To a great extent, small pituitary adenomas 
have a “quiet” presentation and may behave as silent, asymptomatic tumors, in spite of positive 
immunohistochemistry (IHC), while true null-cell adenomas are infrequent (4).
A body of clinical case reports published over the past quarter of century point out to clinically 
relevant, concurrent double, or multiple adenomas of the hypophysis. Multiple pituitary adenomas 
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(MPA) represent simultaneous, but otherwise morphologically 
and IHC distinct masses of the pituitary gland (5) and need to 
be distinguished from mixt, multihormone-secreting tumors 
as such term a single pituitary lesion expressing two or several 
hormones at IHC. Albeit rare in the clinical setting, MPA are 
increasingly suspected when there is an incidental finding upon 
preoperative magnetic resonance imaging (MRI) evaluation of 
the pituitary gland. As they may pose a challenging clinical sce-
nario with regard to imaging localization and optimal first-choice 
approach, occasionally enforcing thorough surgical exploration 
of the pituitary gland to achieve complete removal of functional 
adenomatous tissue, MPA deserve attention as a distinctive 
pituitary pathology.
By screening the literature for isolated cases or case series 
reports, we completed a systematic review to gain insight into 
current knowledge concerning the diagnosis and management 
of MPA. Particularly, clinically relevant aspects were highlighted.
STUDY MeTHODOLOGY
A systematic search of the literature was performed in United 
States National Library of Medicine PubMed, Scopus, and Web 
of Science Core Collection databases with “multiple pituitary 
adenoma/tumor,” “double pituitary adenoma/tumor,” “pituitary 
magnetic resonance imaging,” and “pituitary immunohistochem-
istry” as key words. All identified clinical cases or case series were 
evaluated to be included in the analysis. Of these, only reports 
recording the patients’ clinical data, endocrine evaluation, and 
surgery outcome with IHC exam were retained. Case reports 
presenting metachronous MPA (6) or in which multiple concur-
rent tumors were not clearly documented in spite of a high index 
of suspicion (7) were excluded. Clinical cases reported on two 
different occasions were considered only once (8, 9). Autopsy 
studies lacking clinical and endocrine documentation (10) 
were not included in the analysis but discussed throughout the 
manuscript. However, three cases (two bearing prolactinomas 
and one non-functional adenoma), in which distinct double 
pituitary adenoma was confirmed by MRI, were not subjected to 
surgery (11–13). Double pituitary masses of different origin (e.g., 
adenoma and craniopharyngioma) were not considered (14). 
Ultimately, 63 patients harboring 129 (60 double and three triple) 
synchronous pituitary adenomas fulfilled the study criteria.
PRevALeNCe OF MPA: THe SiZe OF THe 
PROBLeM
Autopsy Reports
Since the first report on multiple pituitary tumors by Kraus 
in 1914 (15), estimates provided by autopsy studies on the 
prevalence of incidentally detected MPA varied widely, ranging 
from 0.01 to 9% of the examined pituitary glands (10, 16–25). 
Furthermore, cases with double, triple, and even 10 multiple 
tumors within one pituitary gland were recognized (17). In a 
large retrospective review of more than 9000 autopsies samples 
from St. Michael’s Hospital records and the Mayo Clinic Tissue 
Registry, Kontogeorgeos et al. described 20 tumor-transformed 
pituitary glands harboring multiple adenomas (i.e., 16 double 
and four triple), in total 44 tumors; size was measured in 30 
tumors, all of which were microadenomas, the majority measur-
ing <3 mm (10). Consistently, subsequent studies showed that 
55–99% of incidentally found adenomas in autopsy materials 
measure <3 mm (21–23). When Kontogeorgeos et al. restricted 
their study to 470 randomly autopsied pituitary glands, a 
prevalence of 0.9% MPA was found, in fact 8.9% of adenomatous 
glands exhibiting multiple tumors (10). As stated by the authors 
themselves, the global prevalence of pituitary adenomas in the 
work of Kontogeorgeos et  al. (10.4%) was twofold to threefold 
lower compared to the reports based on the examination of serial 
sections of the gland (10). Indeed, single-section examination 
allowed detection of pituitary adenomas in 2.7–13% of evaluated 
glands, whereas with serial sectioning of the specimens, the 
incidence reached 8.4–27% (17, 21–23, 25–27).
Regarding MPA, the emphasis should be on their prevalence 
among adenomatous pituitaries, which clearly shows that MPA is 
not an infrequent pituitary pathology. Evaluation of serial 1 mm 
sections of autopsied pituitaries showed a MPA prevalence of 
18.6 and 34.3% in the study of Costello (17) and Burrow (22), 
respectively. About 8.3% double tumors in a small series of 24 
adenomatous glands were found by Tomita et al. (28), while more 
recently Buurman and Saeger reported 17 (5.4%) multiple tumors 
out of 316 affected pituitaries (25). Large autopsy series pointed 
to rates of MPA of 7–10.5% of tumoral glands (17, 21–24, 29), 
the majority of (≈90%) presenting as double adenomas and only 
rarely as three tumors (10, 25). Ectopic tumors (30) or combina-
tion forms, such as anterior pituitary adenoma and posterior 
pituitary granular cell myoblastoma (31), have been reported.
Surgical Specimens
Prevalence data in surgical specimens is rather scarce, mostly 
originating from isolated case reports or specific patient databases 
(Table 1) (5, 29, 32–35).
Overall, the reported prevalence of MPA according to surgical 
data varies from 0.37% detected by Kontogeorgeos et  al. in an 
unselected series of 3000 cases of pituitary adenomas (5) to 1.3% 
observed by Sano in a surgical specimens review of 450 cases 
(32) and 2.6% by Magri in 117 unselected pituitary adenoma 
patients (34) but is highly likely to be underestimated. In a series 
of 600 operated patients referred for pituitary adenoma, Kim 
et al. reported four (0.67%) cases (33), while Ratliff documented 
distinct double pituitary tumors in 1.9% of resected specimens 
(29). Variables including the tumor size or the size and quality 
of the surgical specimen submitted to the pathological exam, 
particularly on second-look interventions, might have impact 
on the estimates. In a small series of Cushing’s disease patients, 
incidentally identified adenomas had an average maximum 
diameter of 3 ± 4 mm (median 2 mm) (29). Detection of a second 
tumor is more difficult in the presence of a macroadenoma (e.g., 
GH-producing tumors), often associated with compression of 
surrounding pituitary tissue, potentially masking a second tumor 
located within the compressed gland (29, 36). Furthermore, 
clinically non-active, intrasellar adenomas, lacking a tumor 
mass effect, even if confirmed by MRI might not represent an 
TABLe 2 | Clinical presentation of MPA.
No. of cases Clinical presentation No. (%)
63 patients Cushing’s syndrome 24 (38.09)
Acromegaly 22 (34.92)
Cushing’s syndrome and acromegaly 3 (4.76)
Hyperprolactinemia syndrome 8 (12.69)
Thyrotoxicosis 1 (1.58)
None 5 (7.93)
TABLe 1 | MPA incidence from five large surgical series, with specifications regarding most frequent clinical presentation.
incidence of multiple pituitary adenomas (MPA) in five large surgical series
Reference No. of glands studied Glands with multiple adenomas Clinical presentation
No. of patients
No. Percent Cushing’s disease Acromegaly
Powers and Wilson (35) 600 1 0.16 – –
Kontogeorgos et al. (5) 3000 11 0.3 2 6
Pantelia et al. (56) 332 1 0.3 1 –
Sano et al. (32) 450 6 1.3 – 6
Ratliff and Oldfield (29) 660 13 1.9 11 –
Kim et al. (33) 600 4 0.6 – 4
Magri et al. (34) 117 3 2.6 – 1
Koutourousiou et al. (8) 548 1 0.18 – 1
February 2016 | Volume 7 | Article 13
Budan and Georgescu Multiple Pituitary Adenomas
Frontiers in Endocrinology | www.frontiersin.org
indication for surgery (13). Hence, the prevalence of MPA might 
be underestimated.
CLASSiFiCATiON AND MORPHOLOGY: 
THe CLUe TO THe UNKNOwN
Synchronous MPA are classified upon macroscopic aspect 
into clearly distinct tumors, recognized as such by neuroradio-
logical imaging and/or surgery (37, 38), and contiguous (collision) 
tumors, which are resected as a single tumor and confirmed as 
MPA by the pathologist (9, 32, 34, 39, 40). An interpolated section 
of non-tumorous pituitary parenchyma should be distinctively 
recognized in individualized adenomas as a histological criterion. 
In the contiguous form, specific cytology, IHC and ultrastructure 
features, in addition to a well-delineated border between the 
tumors prove existence of different cell populations. In spite of 
that, discrete morphological differences between cells may also 
feature single pituitary adenomas (39); vice  versa, similar pat-
terns do not exclude distinct immunoreactivity. However, some 
authors strictly defined MPA based on the evidence of distinct 
tumors (32).
Evaluation of multiple adenomas in autopsy materials most 
commonly demonstrated immune-positivity for PRL (10, 28); 
however, tumors staining for PRL are rather mute in the setting of 
MPA (10). Apart from PRL-immunopositive tumors, the major-
ity of incidentally discovered multiple tumors is represented by 
FSH-secreting and null cell adenomas.
In surgical samples, earlier studies reported 
GH-immunopositive tumors as being most prevalent (10, 12, 32). 
Systematically, analyzing the 63 MPA case reports with IHC data, 
we observed a 50.7% chance that at least one tumor is adreno-
corticotrophic hormone (ACTH)-immunopositive, which is in 
accordance to Cushing’s disease as the most prevalent clinical 
presentation (Table  2). Silent cell PRL-secreting adenomas or 
functional prolactinomas coexist, most frequently, with either 
GH- or ACTH-secreting tumors (Table  3). When excluding 
MPA assigned to genetic forms (i.e., MEN-1 syndrome), double 
GH- and PRL-secreting tumors appear to be the most prevalent 
combination. Indeed, higher rates of mixt ACTH- and PRL-
secreting adenomas are typically seen in patients harboring the 
MEN-1 mutation, otherwise they are regarded as a rather rare 
clinical finding. Nonetheless, in the setting of MPA, PRL-secreting 
tumors were the most common incidental lesion coexisting with 
ACTH-secreting adenomas (Table 2) (7, 29), which potentially 
points toward a genetic common background. However, this was 
not systematically investigated. Other reports indicated combina-
tions of ACTH-producing tumors to gonadotrophic tumors (36, 
41, 42).
Regarding the immunoreactivity, it resulted that 17.82% 
(23/129) adenomas exhibited a pluriendocrine, mixt secretory 
pattern. The most frequent combination immunoprofile was 
represented by mixt GH and PRL secretion, in fact, resembling 
the high incidence of composite GH-PRL secretion encountered 
in single pituitary adenomas. In a review of double pituitary 
adenomas, including tumors with pathological report albeit 
incomplete endocrine evaluation, Iacovazzo et  al. identified 
coexistent ACTH- and PRL-secreting synchronous tumors in 
33% of cases, closely followed by combined non-functional and 
GH-secreting pituitary adenomas (24%), GH- and PRL-secreting 
tumors (10%), and non-functional adenomas combined with 
either ACTH-secreting (7%) or PRL-secreting tumors (7%). In 
most of the cases, tumors staining for PRL were silent (7).
Based on tumor immunoreactivity profile and assigned 
clonality, MPA should be classified into three main patterns (9): 
(1) GH-PRL-TSH-secreting adenomas combined with FSH-LH-
secreting tumors; (2) GH-PRL-TSH producing adenomas com-
bined with ACTH-secreting tumors; and (3) ACTH-secreting 
adenomas combined with FSH-LH-producing tumors, with the 
first two subgroups being identified as the most prevalent ones 
(Table 3).
TABLe 3 | Classification of MPA according to size, macroscopic, and iHC pattern.
No. of analyzed cases Tumor group No. of cases/tumors (%) Clonality
iC No. (%) DC No. (%)
IHC 63 GH-PRL-TSH and LH-FSH 31 (49.2) 17 (54.83) 14 (45.16)
ACTH and GH-PRL-TSH 30 (47.61) 2 (6.66) 28 (93.33)
LH-FSH and ACTH 2 (3.17) 0 2 (100)
Size 23a (49 adenomas) Macroadenomas 5 (10.2)
Microadenomas 44 (89.79)
Macroscopic aspect 49b Contiguous 23 (46.93)
Clearly distinct 26 (53.06)
IHC, immunohistochemistry; IC, identical clonality; DC, different clonality.
a23 case reports (i.e., 49 pituitary adenomas) were identified in that tumor size was assessed by MRI/surgery or IHC evaluation.
b49 case reports in that information was available.
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Specifically, each of the tumors can secrete one or several 
hormones; hence, making different combinations of pituitary 
adenomas possible.
PATHOGeNeTiC CONSiDeRATiONS 
iN MPA
A number of genetic (e.g., oncogenes, tumor suppressor genes, 
and cell cycle abnormalities) or epigenetic (e.g., CpG dinu-
cleotides methylation, expression of micro-RNAs and large non-
coding-RNAs, and modification of histone tails) events appear 
to be involved in pituitary tumor genesis. However, limited 
information is available with regard to oncogenesis of multiple 
adenomas of the pituitary gland.
The Multiple-Hit (Multicentricity) Theory
Coincidental monoclonal expansion of two distinct genetically 
mutated pituitary cell types could result in the development of 
synchronous tumors. Evidence of distinct tumor capsules at 
microdissection of surgical specimens, recognized even in the 
contiguous tumor phenotype (29), favors the concept of a multi-
centric origin of MPA.
The Transdifferentiation Theory
Alternatively, cells of one already constituted pituitary adenoma 
could transdifferentiate into another cell type, with different 
morphologic and phenotypic characteristics including secretory 
features and local behavior.
Insight to the pathogenesis of MPA was gained by immuno-
histochemical localization of transcription factors, which allows 
classification of pituitary tumors according to the lineage of cell 
differentiation irrespective of the tumor hormone substance. 
Occasionally, genetic analysis for clonality has practical value 
as the demonstration of true lineage infidelity in the pathology 
specimen readily suggests multiple adenomas (40), although 
single plurihormonal adenomas exhibiting heterogeneous cell 
populations of different clonal origin were also recognized (43). 
As such, combination patterns in that tumors releasing secretory 
products consistent with multiple clonal proliferations were certi-
fied by genetic analysis in few cases of composite pituitary adeno-
mas (43, 44). Transcription factors immunoprofiling revealed 
in two of three cases of double pituitary adenomas lineages of 
distinct origin, with Pit-1 expression in PRL-secreting cells and 
the hormone-negative cell component expressing SF-1 (34). 
Likewise, Pit-1 was expressed in PRL-secreting or pluriendocrine 
and T-pit in ACTH-secreting adenoma, while double adenoma 
combining T-pit and SF-1 expressing cells resulted in develop-
ment of ACTH- and gonadotroph-cell adenomas, as shown by 
Jastania et al. (40). Double tumors with different clonality rather 
support the true multiple adenomas theory (45), whereas trans-
differentiation might be more plausible in cases of MPA sharing 
immunoreactivity to any of the hormones secreted by one of the 
three different lineages into which pluripotent progenitor cells 
from the normal pituitary gland differentiate (42).
Pituitary tumor-expressed growth factors and hormone recep-
tors may participate in tumor development through auto- or 
paracrine mechanisms (46), and this hypothesis could apply for 
MPA as well. The particular condition of GH-secreting adenomas, 
which release mitogenic GH and IGF-1 to stimulate development 
of a second tumor, is prototypical (5).
Genetic abnormalities might play key roles in tumor genesis 
in patients with MPA as underpinned by positivity for MEN-1 
mutation in 4/63 (6.34%) MPA cases included here, which are 
about 2.3-fold more frequent than expected in adult patients with 
pituitary adenoma (47). In addition to that, MEN-1 gene muta-
tion was also confirmed in one of the patients with hyperprol-
actinemia harboring two distinct lesions on pituitary MRI (11), 
not included in our analysis. Notwithstanding, specific testing for 
genetic causes related to pituitary tumors was not offered to all 
patients, which in addition to the small study population may 
impair data accuracy, thus requiring further studies. In MEN-1 
syndrome, the prevalence of tumors with more than one lineage is 
significantly higher compared to non-MEN-1 cases, with ACTH- 
and PRL-producing tumors as the most prevalent combination 
(48). Furthermore, Kim et al. (33) were able to report two cases 
of familial-isolated pituitary double GH-secreting adenomas 
(FIDPA), unrelated to MEN-1.
Additionally, somatic mutations (e.g., mutation of Gs pro-
tein) extended to more than one pituitary adenoma might be 
involved in the process of multiple tumor formation and have 
been demonstrated, particularly in GH-producing adenoma. 
Transcriptional studies may reveal whether coexisting tumors 
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originate from one cell type (33). About 40% of GH-secreting 
adenomas harbor a Gs protein mutation (49), implying this muta-
tion has a determinant tumorigenic role (50). A somatic muta-
tion in the ubiquitin-specific protease 8 (USP8) gene (51) was 
reported in about one-thirds to two-thirds of ACTH-secreting 
adenomas, which is the most prevalent functional tumor found 
in MPA. Nevertheless, none of the cases with USP8 mutations 
exhibited double or multiple adenomas.
CLiNiCAL MANAGeMeNT OF MPA
Of all cases, 45/63 (71.42%) beard hormonally active tumors in 
our analysis; therefore, recognition of double or multiple pituitary 
tumors within one pituitary gland is prerequisite to avoid failure 
of surgery by missing the causative lesion (29, 41, 52, 53).
It still is a matter of debate, which type of endocrine dysfunc-
tion essentially unravels the disease in patients harboring MPA, 
some case series reports favoring acromegaly (54), whereas others 
argue for Cushing’s disease (7).
Of 63 fully documented clinical cases reported until now, 24 
presented as Cushing’s syndrome (5, 29, 30, 35, 36, 41, 42, 54–58), 
closely followed by acromegaly with 22 cases (5, 9, 32, 33, 39, 41, 50, 
53, 54, 58–63). Of note, synchronous ACTH- and GH-producing 
tumors were confirmed by IHC in seven patients; three of these 
cases expressed clinically as Cushing’s syndrome, one as acro-
megaly, and three were diagnosed with both hyperadrenalism 
and acromegaly (54, 58, 59) (Table  3). However, particularly 
incipient disease clinical features in acromegaly might be mild; 
according to Endocrine Society guidelines, IGF-1 screening in 
each patient with confirmed pituitary mass is recommended (64). 
Hyperprolactinemia in acromegaly patients points out to either 
mixt GH and PRL tumor release or pituitary stalk compression in 
the setting of suprasellar macroadenoma but raises also the pos-
sibility of two independent GH- and PRL-secreting adenomas. 
In agreement to this, Tolis et  al. reported a patient with acro-
megaly and galactorrhea–amenorrhea syndrome caused by two 
separate adenomas, one producing GH and the other PRL (53). 
Furthermore, failure of dopamine agonists’ effect in prolactinoma 
may suggest double pituitary adenoma in certain cases (65).
Apparently, about 1.6–3.3% of Cushing’s disease patients 
exhibit double or multiple pituitary tumors (29). Three cases of 
double pituitary lesions were reported by Meij et al. in patients 
with Cushing’s disease (42). Additionally, two out of three patients 
with double pituitary tumors reported by McKelvie et  al. pre-
sented ACTH-dependent hypercortisolemia (41). By screening a 
Cushing’s syndrome database, Ratliff and Oldfield found double 
pituitary tumors in 13 of 660 operated pituitaries, prospectively 
evaluated (29). Up to the moment, only two clinical cases featur-
ing clearly separated pituitary adenomas, both ACTH-secreting, 
were reported (30, 43). Cushing’s disease may be subclinical (59) 
and easily missed (7, 66).
The source of ACTH hypersecretion in ACTH-
immunoreactive forms of MPA is mainly eutopic due to 
hyperfunctional pituitary corticotroph adenoma cells; however, 
ACTH may also derive from ectopic corticotroph tumor cells 
located in the parasellar area, the neurohypohysis, or the 
pituitary stalk (30, 67). Corticotroph cell nodular hyperplasia 
has been suggested in a small number of patients with Cushing’s 
disease (68), including MPA (42, 55).
Lack of disease remission after effective transsphenoidal sur-
gery in a patient with Cushing’s disease supports, in theory, the 
possibility of residual tumor or MPA in that the incidental non-
functional tumor was removed. Nevertheless, clear distinction 
between persistent disease after unsuccessful surgery and disease 
recurrence should be made (69), as the latter is also increasingly 
reported in cured pituitary ACTH-secreting adenoma (70).
Higher rates of Cushing’s disease among case reports possibly 
reflect more aggressive management enforced by the need to 
cure adrenal hyperfunction. However, variability between stud-
ies is relatively high and the small numbers of cases significantly 
impairs accuracy.
imaging Detection of MPA
Multiple adenomas of the pituitary gland are traditionally known 
as difficult to be detected at preoperative imaging investigation 
(5, 29, 42, 54), the widely accepted reason being the small size 
of at least one of tumors, in several cases <3 mm. Older studies 
reported low accuracy for MRI diagnosis of MPA, such as in the 
case series of Ratliff, where none of the seven cases harboring 
clearly separated double pituitary tumors identified by surgery 
had been previously detected by MRI as such (29). Nevertheless, 
a detailed overview of all MPA clinical case reports clearly shows 
that MRI was able to detect two or even three (56) pituitary 
lesions in about 25% of cases. Except for the five ACTH-secreting 
adenomas in the series of Ratliff, where MRI was non-diagnostic 
(29), a finding which is in agreement to up to about 40% of cases 
of Cushing’s disease having normal MRI (71), a single tumor 
image or, alternatively, ill-defined abnormalities, such as an asym-
metric, inhomogeneous appearance of the gland (55) or a global 
increase in the pituitary volume (30) were noted in most patients, 
which might prompt the neurosurgeon to careful exploration of 
the gland. Most challenging situations remain contiguous MPA, 
resulting in single tumor appearance, even on high-resolution 
MRI exam (34) or macroadenomas masking small coexisting 
tumors (36, 57). As true MPA are rare, false-positive findings of 
double or multiple tumors on pituitary MRI might be detected; 
thus, diagnosis is confirmed following pathological exam.
High-resolution MRI techniques need to be employed in 
hormonally active tumors with non-diagnostic imaging tests 
(54). Thin-sliced and dynamic MRI represents a readily accessible 
option to improve resolution and increasingly detect multiple 
lesions. Alternatively, 3.0-T MRI could detect pituitary microad-
enomas not identified by 1.5-T MRI imaging (72). On the other 
hand, the higher sensitivity attributed to the higher field strength 
in >3.0-T MRI devices may also increase the likelihood of false 
positive results, and images have to be interpreted cautiously. 
Use of spoiled gradient recalled acquisition (SPGR) sequences 
improves detection of ACTH-producing adenomas (73, 74). 
Recently, more advanced techniques, such as MET-PET/3.0-T 
MRI, showed higher sensitivity in the detection of ACTH-
secreting pituitary microadenomas compared to traditional and 
dynamic MRI (75, 76).
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Surgery and Postoperative evaluation
Confirmed microadenoma at initial pituitary exploration prompts 
to the careful inspection of the anterior and lateral surfaces of the 
gland for a second tumor (29, 52) as more than 50% of small 
tumors, particularly GH- and PRL-secreting adenomas, present 
on the surface of the gland (5). Exploratory pituitary surgery 
should be reserved only to cases with high suspicion or during 
second-look surgery as well as for ACTH-secreting tumors with 
normal MRI and non-diagnostic inferior petrosal sinus sampling 
(IPSS). Intraoperative pituitary imaging [iUltrasonography 
(iUS)/iMRI] seems be useful to assure complete tumor removal 
in certain cases. Residual tumor detection is facilitated with iMRI, 
particularly when located in the para- or suprasellar area (77), to 
achieve rates of resection of up to 96% in unselected series (78); 
however, the sensitivity of the method significantly decreases 
when remnant lesions are smaller than 3 mm (79). Few studies 
reported on the use of iUS to allow targeted resection of small, 
hyperechoic pituitary adenomas, even in MRI-negative cases, as 
in the typical condition of Cushing’s disease (80, 81), although 
limited experience is available. Immunohistochemistry allows 
the exclusion of false double pituitary lesions by detecting distinct 
immunochemical signatures in surgical specimens.
Isolated case reports evoke Cushing’s disease patients in whom 
the surgeon removed a PRL- or GH-secreting adenoma while the 
ACTH-secreting tumor was identified and resected at reoperation 
(29, 41). Apart from absent ACTH stain on IHC, lack of postsurgi-
cal hypoadrenalism is highly suggestive of tumor persistence in 
operated Cushing’s disease patients (57). Even if both tumors are 
correctly removed, unequivocal diagnosis of MPA is difficult when 
adenomas show identical immunoreactivity; in these cases, vari-
ability in cells size, conventional staining, and cytoplasm appear-
ance (36, 55) or presence of a thin lamellae of compressed normal 
pituitary tissue separating the tumors might be of help. Electron 
microscopy scanning may provide additional information (e.g., 
degree of granularity, changes in Golgi apparatus, or presence 
or absence of fibrous bodies) and should be considered when 
available (32, 33, 39, 40, 54, 65). Furthermore, quantitation of 
O-methylguanine-DNA methyltransferase (MGMT) immuno-
expression, the Ki-67 nuclear labeling index, or supplemental 
transcription factors (82) may show significant differences among 
tumors in patients suspected for multiple adenomas.
CONCLUSiON
Autopsy series indicate a prevalence of 7–10% MPA of all 
adenomatous pituitary glands, which is highly discordant to 
exceedingly rare clinical and/or operative reports (i.e., 1–1.5% 
of pituitary adenomas), thus suggesting the many cases of MPA 
that remain undiagnosed, since only rarely these multiple tumors 
are clinically relevant. Notwithstanding, double lesion images 
or equivalent abnormalities on high-resolution MRI scan are 
not rare in patients harboring MPA and should always point to 
careful surgical pituitary exploration, particularly in Cushing’s 
syndrome or acromegaly patients. However, definitive diagnosis 
should be concluded based upon pathological examinations. 
Persistence of endocrine disturbances after pituitary surgery 
leads to a high index of suspicion for MPA. Up to this moment, 
the etiopathogeny of MPA remains elusive, in spite of various 
theoretical concepts and higher prevalence of MEN-1 mutation 
among genotyped cases. Further, molecular analysis will provide 
new insights into the pathogenesis of pituitary adenomas and the 
mechanisms of multidirectional phenotypic differentiation.
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